Skip to main content
Drotrecogin alfa (activated) in sepsis: Initial experience with patient selection, cost, and clinical outcomes.
All Scholarly Works
  • Thomas Higgins, MD, Baystate Health
  • Jay Steingrub, MD, Baystate Health
  • Mark Tidswell, MD, Baystate Health
  • William McGee, MD, Baystate Health
  • Gary Tereso, Baystate Health
Document Type
Article, Peer-reviewed
Publication Date
During a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated for sepsis in a 24-bed medical-surgical intensive care unit. Drotrecogin alfa, activated was administered 46 times to 44 patients (3% of all intensive care u
Publication ISSN
Citation Information
J Intensive Care Med. 2005 Nov-Dec;20(6):339-45.